Latest Conference Articles

Anat Loewenstein, MD, sat down with Hattie Hayes of Ophthalmology Times Europe to discuss the implication of longitudinal AI-based fluid quantification for at-home monitoring from the Angiogenesis Exudation and Degeneration 2024 event.

Dr Carl Regillo provided an overview of topline results – and a deep dive into subgroup analyses – of DAVIO 2 trial data

Carl D. Regillo, MD, FACS, FASRS, discussed recent data from the DAVIO 2 trial in his presentation at the virtual Angiogenesis, Exudation, and Degeneration 2024.

Dr. Carl Regillo provided an overview of topline results and a deep dive into subgroup analyses of DAVIO 2 trial data.

Sydney M Crago, the editor of Modern Retina, talks with Arshad M Khanani, MD, MA, FASRS, about the expanded efficacy data from the GATHER 2 trial for geographic atrophy (GA).

Sydney M Crago, the editor of Modern Retina, talks with Arshad M Khanani, MD, MA, FASRS, about the expanded efficacy data from the GATHER 2 trial for geographic atrophy (GA).

Carl Danzig, MD, sat down with Martin David Harp of Ophthalmology Times to discuss his presentation AVD-104 for Geographic Atrophy: Glyco-immunologic modulation of macrophage activity from the Angiogenesis Exudation and Degeneration 2024 event.

Early-onset drusen maculopathy (EODM), is part of the age-related macular degeneration (AMD) phenotype that occurs in individuals under 55 years of age.

EODM may be an ideal candidate for development of complement gene therapy due to the high-impact genetic variants.

SriniVas R. Sadda, MD, sat down with David Hutton of Ophthalmology Times to discuss his presentation about precursor lesions for development of atrophy and AMD from the Angiogenesis Exudation and Degeneration 2024 event.

Multimodal technology bridges the gap between advanced age-related macular degeneration (AMD) biomarkers and clinical features.

Researchers aimed to develop a translational map to understand how advanced imaging biomarkers manifest in typical diagnostic imaging

This presentation will outline the safety and bioactivity of KSI-501ABC in patients with diabetic macular edema (DME).

The afternoon sessions begin after lunch and continue well into the evening at the Angiogenesis, Exudation, and Degeneration 2024 meeting

The one-day event will be held online Saturday, February 3, 2024, and is sponsored by the Bascom Palmer Eye Institute, University of Miami Health System

The afternoon sessions promise to be engaging and informative in this virtual conference.

John T. Thompson, MD, FASRS, shares pearls for navigating the diverse landscape of career paths in ophthalmology as the Distinguished Guest Speaker at the 24th Annual Retina Fellows Forum.

This meeting, scheduled for Saturday, February 3, 2024, is a 1-day virtual event sponsored by the Bascom Palmer Eye Institute, Miami, University of Miami Health System.

Leanne Clevenger, MD, described a case that highlights varying approaches and protocols for addressing a complex case of retinal detachment repair in a patient with trauma to the globe.

David Hutton of Ophthalmology Times talks with Adrienne Scott, MD, FASRS, about her part in a panel discussion detailing emerging therapies for AMD.

David Hutton of Ophthalmology Times talks with Sunir Garg, MD about his surgical video panel at this year's Retina Fellows Forum.

Allen Ho, MD, FACS, FASRS, will make a presentation at the meeting, to be held virtually on February 3.

Bonnie An Henderson, MD, previews the EnVision Summit 2024, scheduled for February 16 to 19 in Puerto Rico, highlighting its family friendly atmosphere, diverse specialty coverage, and new sessions on leadership and health equity.

Roger A. Goldberg, MD, MBA, presents a post hoc analysis of the Phase 2/3 PHOTON trial, offering insights into the potential benefits of 8 mg aflibercept in managing fluid reaccumulation, particularly in cases of diabetic macular edema.

Principle findings showed that aflibercept 8 mg demonstrated similar improvements in BCVA and CST when compared to the 2 mg dose of aflibercept.

David A. Eichenbaum, MD, discusses the promising aspects of gene augmentation for treating common retinal diseases, addresses concerns about perpetual protein production, and considers the potential positive impact on patients by reducing treatment burdens.

David Eichenbaum, MD, discussed the status of the technology at the Retina 2024 meeting in Maui.